Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving…
Oncology
-
-
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new bispecific antibody, Ziihera (zanidatamab), for…
-
Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
-
FDA approves label updates for BMS’ CAR T cell therapies
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates…
-
Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies
Porton Advanced Solutions and EVA Pharma have signed a memorandum of understanding (MoU) to enhance the development and manufacturing capabilities…
-
Revolution Medicines partners Royalty Pharma on $2bn funding
Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy…
-
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with locally…
-
Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the…
-
NSW government invests $13.39m in life-changing therapies
The government of New South Wales (NSW), Australia, has announced an investment of A$20.7m ($13.39m) in access to life-changing therapies…
-
Orion and Glykos extend ADC collaboration
Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs). Under the research partnership…
